HealthDay on MSN3h
ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related DiseaseFor patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...
Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback